YZFyzfpeptide.comTirzepatide5mgFor Research Use Only
1 / 1
Research product specification
TR5
Tirzepatide
For Research Use Only. Not for human or veterinary use.
Tirzepatide is listed for legitimate laboratory and research procurement. This 99%+ research-use product is available in 10 listed specifications. Review product codes, storage guidance and COA status, then request a wholesale quotation. Published COA documentation is available for selected specifications.
Volume discounts are available for larger purchasing plans. Please contact us for a quotation.
Delivery includedUsually within 7 days after dispatch
Quality resolutionRefund or replacement when approved
24/7 contactWholesale assistance on WhatsApp
Product profile
About Tirzepatide
Tirzepatide is a synthetic 39‑amino acid linear peptide and the first‑in‑class dual agonist of the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors. It works by simultaneously activating both incretin receptors to enhance glucose‑dependent insulin secretion, suppress glucagon release, delay gastric emptying, and induce significant appetite suppression via central pathways. Compared to single‑receptor agonists, tirzepatide leverages synergistic dual pathways to exert superior metabolic regulation, demonstrating exceptional efficacy in both glycemic control and weight reduction. Its extended pharmacokinetic profile enables once‑weekly subcutaneous administration with stable therapeutic concentrations.
Main functions
1.Superior Weight Reduction: Dual incretin agonism delivers stronger satiety and reduced caloric intake, with clinical data showing greater weight loss compared to existing GLP‑1‑based therapies.
2.Potent Glycemic Control: Glucose‑dependently modulates insulin and glucagon, effectively lowering fasting and postprandial blood glucose with a minimal risk of hypoglycemia.
3.Multi‑facets Metabolic Improvement: Comprehensively improves lipid profiles (triglycerides, total cholesterol, LDL‑C) and contributes to favorable blood pressure regulation.
5.Cardiovascular Benefits: Demonstrated trends toward reduced cardiovascular event risk in clinical studies, providing added protection for high‑risk populations.
6.Once‑Weekly Convenience: Long‑acting design allows for a single weekly subcutaneous injection, greatly enhancing long‑term treatment adherence.
Recommended audience
Obese or overweight individuals requiring substantial weight loss, especially those with suboptimal response to existing weight‑management regimens.
Patients with type 2 diabetes, particularly those who need potent glycemic lowering alongside significant weight reduction.
Individuals with multiple metabolic disorders, including dyslipidemia, hypertension, and fatty liver disease.
Users seeking comprehensive metabolic and cardiovascular benefits from a single therapeutic agent.
Order formatOne box accepted
QuotationConfirmed on WhatsApp
DeliveryShipping and duties included
DocumentationPublished COA or available on request
Research product specification
Product information
Tirzepatide is listed for legitimate laboratory and research procurement. This 99%+ research-use product is available in 10 listed specifications. Review product codes, storage guidance and COA status, then request a wholesale quotation. Published COA documentation is available for selected specifications.
Handling information
Storage guidance
Keep unopened lyophilized products protected from light and moisture; store at 2-8°C short term or -20°C long term. After reconstitution, refrigerate according to product documentation and minimize freeze-thaw cycles.
Customer-first resolution
Report quality concerns within 14 days of delivery
Contact us with the order number, batch details and available photos. Opened products are accepted for review. When a quality claim is approved, you may choose a full refund or replacement shipment.
